CLL定向治疗对DLBCL型Richter转化与初发DLBCL预后影响
该全国性队列研究比较了2002至2022年间6525例初发DLBCL(dnDLBCL)与383例DLBCL型Richter转化(DLBCL-RT)患者的结局,其中260例为未经治疗的CLL转化(RT:TN-CLL),123例为经治CLL转化(RT:TE-CLL)。结果显示RT:TE-CLL患者的中位至下一治疗或死亡时间(TTNTd)和中位总生存期(OS)均劣于RT:TN-CLL和dnDLBCL,而RT:TN-CLL的TTNTd劣于dnDLBCL但OS接近dnDLBCL。
要点
- RT:TE-CLL患者TTNTd和OS显著劣于RT:TN-CLL及dnDLBCL。
- RT:TN-CLL患者TTNTd劣于dnDLBCL,但OS接近dnDLBCL。
- RT:TN-CLL或仍可从化学免疫治疗中获益,RT:TE-CLL需新型疗法。
核心结论
- RT:TE-CLL患者TTNTd和OS劣于RT:TN-CLL和dnDLBCL,RT:TN-CLL的TTNTd劣于dnDLBCL但OS接近dnDLBCL。
研究设计与样本
- 全国性队列研究,纳入2002至2022年6525例dnDLBCL和383例DLBCL-RT患者。
主要发现
- dnDLBCL、RT:TN-CLL和RT:TE-CLL的中位TTNTd分别为4.83年、1.43年和0.46年。
- 一线治疗后中位OS分别为9.42年、5.22年和0.72年(p < 0.001)。
- 高有效性亚组中,dnDLBCL中位OS为9.85年(CI: 9.16-10.70),RT:TN-CLL为6.07年(CI: 4.23-不可估计),RT:TE-CLL为1.15年(CI: 0.76-3.66),RT:TN-CLL与dnDLBCL的OS差异无统计学意义。
临床怎么用
- RT:TN-CLL患者可考虑化学免疫治疗,RT:TE-CLL患者需探索新型治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) type Richter transformation (DLBCL-RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL-RT with or without previous CLL-directed therapy compared to dnDLBCL between 2002 and 2022. We included 6525 patients with dnDLBCL and 383 patients with DLBCL-RT, of whom 260 had Richter transformed treatment-naïve CLL (RT:TN-CLL) and 123 had Richter transformed treatment exposed CLL (RT:TE-CLL). Median time to next treatment or death (TTNTd) was 4.83 years, 1.43 years and 0.46 years for patients with dnDLBCL, RT:TN-CLL and RT:TE-CLL respectively. Median overall survival (OS) following first-line treatment was 9.42, 5.22 and 0.72 years for dnDLBCL, RT:TN-CLL and RT:TE-CLL respectively (p < 0.001). In a high-validity subcohort, OS did not differ significantly between RT:TN-CLL and dnDLBCL (median OS 9.85 years [CI: 9.16-10.70] for dnDLBCL, 6.07 years [CI: 4.23-not estimable] for RT:TN-CLL and 1.15 years [CI: 0.76-3.66] for RT:TE-CLL). In conclusion, patients with RT:TE-CLL had inferior TTNTd and OS compared to RT:TN-CLL and dnDLBCL. RT:TN-CLL demonstrated inferior TTNTd compared to dnDLBCL, but OS approached that of dnDLBCL. This indicates that for patients with RT:TN-CLL, chemoimmunotherapy may still be an effective modality, while patients with RT:TE-CLL need novel treatment options.
引用
- Katsimigas A, Werling M, Frederiksen CM, et al. Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort. Br J Haematol. 2026. PMID: 42381485. doi:10.1111/bjh.70651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。